Morphine-6-glucuronide Derivatives with Heteroaromatic Substituents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current morphine-6-glucuronide derivatives for pain treatment have limitations in terms of efficacy and stability, particularly in their preparation and purification processes, which affect their clinical application.
Innovation Solution
Development of specific morphine-6-glucuronide derivatives represented by formula (I), including heteroaromatic groups and their preparation through a multi-step process involving protective groups, coupling reactions, and deprotection steps, to produce compounds that exist as enantiomers, diastereoisomers, and their mixtures, including racemic forms, in base or acid addition salt, hydrate, or solvate states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If morphine-6-glucuronide derivatives are prepared using conventional methods, then the basic analgesic function is achieved, but the stability and efficacy are insufficient for optimal clinical application
Solution Approach 1:
The patent introduces a preliminary protection step where hydroxyl groups are protected as silyl ethers (TMS or TBDMS) before performing the coupling reaction with the morphine-6-glucuronide derivative. This preliminary action prevents unwanted side reactions and ensures the stability and efficacy of the final product by controlling the reactivity of functional groups during synthesis.
Solution Approach 2:
The patent uses a silyl protecting group as an intermediary to temporarily mask the hydroxyl group's reactivity during the coupling reaction. This intermediary allows the reaction to proceed with enhanced stability and selectivity, and can be easily removed later to reveal the desired product with improved efficacy.
2Ease of manufacture
If the preparation process is simplified, then ease of manufacture is improved, but manufacturing precision and product purity may be compromised
Solution Approach 1:
The patent segments the synthesis into distinct steps: protection of hydroxyl groups, coupling reaction with morphine-6-glucuronide derivative, and deprotection. This segmentation allows each step to be optimized independently, maintaining manufacturing precision and product purity while keeping the overall process manageable and relatively simple.
Solution Approach 2:
The patent employs specific reaction parameters including the use of trimethylsilyl trifluoromethanesulfonate as a catalyst in dichloromethane solvent at controlled temperatures. These parameter changes ensure high stereochemical control and product purity without requiring overly complex manufacturing procedures.
3Reliability
If specific heteroaromatic substituents are introduced to enhance analgesic efficacy, then pain management effectiveness is improved, but the complexity of the molecular structure increases
Solution Approach 1:
The patent introduces heteroaromatic substituents (such as pyridyl, pyrimidyl, or triazoly l groups) at specific local positions on the glucose moiety of the morphine-6-glucuronide derivative. This local modification enhances analgesic efficacy through targeted molecular interactions while keeping the rest of the molecular structure relatively simple and manageable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthesized compounds demonstrate enhanced stability and efficacy as analgesics, offering improved pain management options with varied substitution patterns and forms, facilitating their use in clinical settings.
Implementation Method 1
compounds of formula (I) can be prepared according to the following process illustrated by diagram 1. In a first step, a compound of general formula (II) can be coupled to a compound of general formula (V), in which R1 is as defined in general formula (I), PG 2 is a protecting group such as a benzoyl group and LG is an activating group such as a trichloroacetimidate
Implementation Method 2
In a second step, the compound of general formula (VI) is reduced and deprotected simultaneously, for example in the presence of lithium and aluminum hydride, in a solvent such as tetrahydrofuran, at the reflux temperature of the reaction medium
Data Source
AI summary
The invention relates to derivatives of morphine-6-glucuronide having formula (I) wherein R1 is a 5-membered heteroaromatic group optionally substituted by one or more substituents selected from among halogen atoms and (C1-C4)alkyl, halogen, hydroxyl, halo(C1-C4)alkyl, halo(C1-C4)alkyloxy, (C1-C4)alkyloxy, aryl(C1-C4)alkyl and aryl groups, said aryl group being optionally substituted by one or more groups selected from among (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxyl and (C1-C4)alkyloxy groups, in the form of a base or acid addition salt, as well as in hydrate or solvate form. The invention also relates to the preparation method thereof and to the use of same in therapeutics.